Summit Therapeutics Inc. SMMT

US Biotechnology

$18.03 ▲ +1.07% (+$0.19)

🔥 High Short Interest

Open $17.84

Prev Close $17.84

Day Range $17.54 – $18.15

52W Range $12.07 – $29.23

Market Cap $14.27B

Beta -1.45

EPS (TTM) $-1.12

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2004-10-14
Shares Out.	799,730,000
Website	smmttx.com/ ↗
Phone	18004831140
Employees	265
Revenue	$0
Gross Profit	$0
Net Income	-$208.4M
Free Cash Flow	-$526.9M
Total Assets	$692.9M
Total Liabilities	$128.2M
Equity	$564.7M

About Summit Therapeutics Inc.

Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.

Summit Therapeutics Inc. is a publicly traded company under the ticker symbol SMMT on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.